Russia completes early trials of second potential Covid-19 vaccine: Ifax
Russia registered its first vaccine candidate, developed by Moscow’s Gamaleya Institute, in August. Late-stage trials of this vaccine, due to involve 40,000 participants, were launched last week
Siberia's Vector virology institute on Tuesday completed early-stage human trials, known as Phase II, of a second potential Russian vaccine against Covid-19, the state consumer safety watchdog was cited by the Interfax news agency as saying.
Russia registered its first vaccine candidate, developed by Moscow's Gamaleya Institute, in August. Late-stage trials of this vaccine, due to involve 40,000 participants, were launched last week.
Human trials of the second potential Covid-19 vaccine, a peptide-based jab, began on July 27 and involved a group of 100 volunteers, Interfax cited watchdog Rospotrebnadzor as saying.
Keep updated, follow The Business Standard's Google news channel
"Today ... the final group of 20 volunteers was released from hospital," said in a statement. "All 100 volunteers were vaccinated with two doses and have completed a 23-day monitoring period in hospital. The volunteers are feeling good."
Results are due to be published on Sept. 30, Interfax said.
